Abstract: A computer-implemented method is provided. The method includes generating an augmented reality environment, determining a number of virtual avatars requiring an avatar space within said augmented reality environment, determining a number of physical avatar spaces that are available for occupation within the augmented reality environment, comparing the number of virtual avatars requiring an avatar space to the number of available physical avatar spaces and, when the number of virtual avatars requiring an avatar space within the augmented reality environment is less than or equal to the number of available physical avatar spaces, assigning a different available physical avatar space to each virtual avatar.

Abstract: Provided are methods of making a pharmaceutical composition comprising: providing a matrix solution/suspension comprising a matrix former, a structure former, 0.1-1.5 wt. % anti-aerating agent, and a solvent; mixing a plurality of hydrophobic particles into the matrix solution/suspension to form a pharmaceutical suspension; and dosing the pharmaceutical suspension into preformed blister packs, wherein a dosed weight of the dosed pharmaceutical suspension is within 10 % of a target dosed weight.

Abstract: The present invention relates to crosslinkable ink compositions and the preparation and use thereof.

Abstract: A wearable device, system and method. The wearable device comprises a frame portion and a body portion. The frame portion is formed from a metallic material and the body portion is formed from a non-metallic material. The frame portion is configured to partially surround the body portion. The body portion supports at least one passive or active tag thereon such that the tag is operable through an opening in the frame portion.

Abstract: An analyte monitoring assembly for monitoring one or more analytes in a bodily fluid of a user includes a housing configured to be mounted on a body of a user and sensor electronics arranged within the housing. An analyte sensor includes a body portion coupled to the sensor electronics and arranged within the housing and one or more tail portions configured to be positioned in the body of the user. The analyte sensor further includes a first electrode comprising a first active area for detecting a first analyte, and a second electrode comprising a second active area for detecting a second analyte.

Abstract: A method of video evaluation for a video comprising successive video frames comprises the steps of generating optical flow vectors for at least a subset of corresponding pixels between frame pairs, calculating a difference between corresponding optical flow vectors of successive frame pairs, and evaluating the resulting differences with respect to a predetermined criterion, to identify respective frame pairs for further processing.

Abstract: A method of video evaluation includes: for a current video frame, generating two or more metrics from the list consisting of an interframe greyscale delta sum of absolute differences between the current and immediately preceding frame, a first interframe colour delta sum of absolute differences for at least a first colour channel between the current and immediately preceding frame, a second interframe colour delta sum of absolute differences for at least a second colour channel different to the first colour channel between the current and immediately preceding frame, for a first colour channel of the current video frame, a delta between mean and current measurements of a property of the first colour channel, the mean being derived over a predetermined period of time, and for a second colour channel of the current video frame, a delta between mean and current measurements of a property of the second colour channel, the mean being derived over a similar predetermined period of time; generating respective z-scor

Abstract: A method of video evaluation for a video comprising successive video frames comprises the steps of, for successive video frame images: generating a perceptual hash of at least a first portion of a respective image, comparing the generated perceptual hash of a current video frame image with a corresponding perceptual hash of at least one preceding video frame image, and if a difference between the compared perceptual hashes exceeds a predetermined threshold, then identify the one preceding video frame as the boundary of a scene cut within the video.

Abstract: An image-based program state analysis method comprises the steps of, for a given image generated by a program, identifying at least a first location within the image occupied by a respective user interface element; identifying in the image a predetermined point on the respective user interface element; identifying the information conveyed by the respective user interface element, with reference to the predetermined point; and outputting the information for subsequent analysis.

Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising coated API. Excess coating material that is not bound to coated API may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated API and to minimize aeration of API when mixed into suspension.

Abstract: A wheel assembly bushing for in-wheel electric motors where the bushing includes a hydraulic chamber positioned within a resilient sleeve of the bushing and a helical fluid channel that extends helically about an inner bushing member between first and second fluid channel ends, which are arranged in fluid communication with the hydraulic chamber. An outer body extends annularly about the resilient sleeve, which permits relative movement between the inner bushing member and the outer body. The fluid channel is configured to produce inertance. This inertance, when combined with other damping and stiffness effects of the wheel assembly bushing, provides phase and magnitude shifts between force and velocity, which ultimately reduce magnetic gap deformation in the in-wheel electric motor.

Abstract: A gateway apparatus comprising circuitry configured to wirelessly receive, in a Bluetooth Low Energy advertising packet, an identifier of a communication apparatus and an indicator of whether the communication apparatus is requesting a wireless connection with a gateway apparatus; establish, in response to the Bluetooth Low Energy advertising packet indicating the communication apparatus is requesting a wireless connection with a gateway apparatus, a wireless connection with the communication apparatus; receive, via the established wireless connection, information from the communication apparatus associated with the identifier of the communication apparatus; and transmit the received information to a web service.

Abstract: The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula.

Abstract: The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins.

Abstract: Combination Treatments for Melanoma This specification discloses the use of an ATR inhibitor in combination with an immune checkpoint inhibitor for the treatment of melanoma in a patient who has previously received immunotherapy.

Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising Ibuprofen using solventless mixing methods. Excess coating material that is not bound to coated Ibuprofen may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated Ibuprofen and to minimize aeration of Ibuprofen when mixed into suspension.

Abstract: A method for identifying a cutscene in gameplay footage, the method comprising: receiving a first video signal and a second video signal each comprising a plurality of images; creating a first video fingerprint comprising a plurality of signatures, each signature of the plurality of signatures based on at least one image of the plurality of images in the first video signal; creating a second video fingerprint comprising a plurality of signatures, each signature of the plurality of signatures based on at least one image of the plurality of images in the second video signal; comparing the first video fingerprint with the second video fingerprint; and identifying a cutscene when at least a portion of the first video fingerprint has at least a threshold level of similarity with at least a portion of the second video fingerprint.

Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions using solventless mixing methods. Excess coating material that is not bound to a coated API particle may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Specifically, a coating ratio and/or a dosing ratio can be used to minimize the residual amount of excess unbound coating material to minimize agglomeration of coating material during storage. In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition comprising: 65-85% w/w API particles; 15-30% w/w coating material coating the API particles; and 3-15% w/w matrix surrounding the coated API particles, wherein the pharmaceutical composition comprises a disintegration time rate of less than 10 seconds for at least six months under storage conditions of at least 25° C. and at least 60% relative humidity.

Abstract: This specification discloses the use of an ATR inhibitor, preferably in combination with a taxane, for the treatment of cancer in a particular subset of patients who have previously received immunotherapy.

Abstract: Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions using solventless mixing methods. Excess coating material that is not bound to a coated API particle may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Specifically, a coating ratio and/or a dosing ratio can be used to minimize the residual amount of excess unbound coating material to minimize agglomeration of coating material during storage. In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition comprising: 65-85% w/w API particles; 15-30% w/w coating material coating the API particles; and 3-15% w/w matrix surrounding the coated API particles, wherein the pharmaceutical composition comprises a disintegration time rate of less than 10 seconds for at least six months under storage conditions of at least 25° C. and at least 60% relative humidity.